• Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) is currently considered the gold standard first-line therapy for chronic lymphocytic leukemia (CLL). (ashpublications.org)
  • We report the preplanned subgroup analysis of 140 previously untreated, fit CLL patients who received obinutuzumab plus fludarabine and cyclophosphamide (G-FC). (nature.com)
  • Standard intravenous/oral doses of fludarabine and cyclophosphamide were administered on D1-3 of C1-6. (nature.com)
  • In this ongoing Phase II multicenter study, 55 heavily pretreated patients with relapsed/refractory DLBCL, including almost 50% without a response to autologous stem cell transplantation (ASCT), were treated with fludarabine/cyclophosphamide lymphodepletion, followed by a dose of JCAR17. (medpagetoday.com)
  • Most patients are treated with oral prednisone, with or without a cytotoxic/immunosuppressive agent, such as methotrexate, cyclophosphamide, or chlorambucil, or a tumor necrosis factor (TNF)-alpha antagonist. (medscape.com)
  • Methods: We retrospectively analyzed 40 patients with metastatic breast cancer treated with low doses of Cyclophosphamide and/or Methotrexate and/or Capecitabine in a single center from June 2009 to April 2014. (scirp.org)
  • The most frequent drugs administered were cyclophosphamide, methotrexate and capecitabine alone. (scirp.org)
  • 10 % of body surface involvement), whose lesions did not heal completely and those who continued to develop new lesions while on adequate doses of daily corticosteroids with or without adjuvants (azathioprine, dapsone, or methotrexate) were included. (cdlib.org)
  • 85% for historical regimens (ie, cyclophosphamide/methotrexate/fluorouracil) are known to affect breast cancer survival. (jnccn.org)
  • Landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. (jnccn.org)
  • Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
  • Fifty-seven patients received busulfan 16 mg/kg and cyclophosphamide 120 mg/kg, and eight received busulfan at doses between 15 and 17 mg/kg and cyclophosphamide at doses 100-200 mg/kg as preparative regimens. (elsevierpure.com)
  • Historically, most cytotoxic treatment regimens have been developed to be used at its maximum tolerated dose (MTD), in order to achieve better tumor control. (scirp.org)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • This report summarizes the clinical course of 17 patients with non-Hodgkin's lymphomas who were treated with high dose intermittent intravenous cyclophosphamide between 1966 and 1968. (karger.com)
  • Pulse intravenous cyclophosphamide without a concomitant corticosteroid pulse has also been used in recalcitrant cases of pemphigus with encouraging results [ 7 , 8 ]. (cdlib.org)
  • A retrospective review was performed on the toxicity and response to one cycle of dose-intense cyclophosphamide/etoposide, followed by consolidation in patients with refractory or previously untreated, high-risk non-Hodgkin's lymphoma (NHL). (duke.edu)
  • The purpose of this study was to determine the maximally tolerated dose of doxorubicin administered during two cycles of intensive chemotherapy with cyclophosphamide and doxorubicin without stem cell support in patients with advanced cancer and to assess the cumulative cardiac toxicity of the regimen by noninvasive radionuclide imaging and by pre- and postchemotherapy endomyocardial biopsies. (elsevierpure.com)
  • A single patient experienced a grand mal seizure associated with orthostatic hypotension, which was considered the dose-limiting toxicity. (elsevierpure.com)
  • We conclude that two courses of high-dose cyclophosphamide and doxorubicin using granulocyte colony-stimulating factor are feasible and safe with tolerable myocardial toxicity as evidenced by serial endomyocardial biopsies. (elsevierpure.com)
  • The dose- limiting toxicity encountered was a grand mal seizure. (elsevierpure.com)
  • The following data were collected: age, hormone and epidermal growth factor receptor 2 (HER-2) status, number of lines of chemotherapy prior to and after low-dose metronomic treatment, duration of metronomic treatment, toxicity reason for treatment discontinuation. (scirp.org)
  • Pulse cyclophosphamide has fewer side effects than traditional cyclophosphamide administration with regard to urinary bladder malignancies and gonadal toxicity [ 9 , 10 ]. (cdlib.org)
  • This will increase the toxicity potential of the cyclophosphamide. (marvistavet.com)
  • We therefore investigated whether such metronomic therapy with the alkylating agent cyclophosphamide (CTX) could be effectively combined with immunotherapy eliciting tumor-reactive CTLs. (ox.ac.uk)
  • Whereas both metronomic and maximum tolerated dose delivery of CTX did cause deletion of proliferating tumor-specific CTLs in the blood, this deletion occurred with slower kinetics with the metronomic schedule. (ox.ac.uk)
  • It is well known that all these low-dose schedules have a favorable safety profile and may provide an adequate tumor control in patients with metastatic breast cancer. (scirp.org)
  • The presence of a spinal cord tumor or another condition that is exerting pressure on the spinal cord, vitamin B12 deficiency, or a history of radiation therapy to or cyclophosphamide injection into the spinal cord excludes the possibility of a diagnosis of transverse myelitis. (encyclopedia.com)
  • In mouse models implanted with human lymphoma tissue, the researchers showed that high doses of the drug, but not normal doses, damaged tumor cells in a way that severely stressed the lymphoma cells. (medindia.net)
  • Cyclophosphamide and piroxicam are used together to address some sarcomas in dogs as a means of addressing the tumor with reduced potential for the side effects listed below. (marvistavet.com)
  • Other oncologists do not like to reduce the cyclophosphamide dose without evidence of infection as reducing the cyclophosphamide dose will give the tumor an advantage and possibly jeopardize the remission. (marvistavet.com)
  • In patients with breast cancer receiving adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D), we evaluated the impact of chemotherapy total cumulative dose (TCD), and early (FEC) versus late (D only) dose reductions, on survival outcomes. (jnccn.org)
  • The better tolerance, high response rate, and encouraging 2-year survival of this regimen in combination with further dose-dense consolidation in patients with high-risk NHL are encouraging. (duke.edu)
  • This study reviews results of a radiation-free preparative regimen consisting of busulfan and cyclophosphamide in 65 unrelated allogeneic bone marrow transplant recipients. (elsevierpure.com)
  • Busulfan/cyclophosphamide is an effective preparative regimen in unrelated bone marrow transplantation permitting adequate engraftment and a low relapse rate. (elsevierpure.com)
  • We extended our prospective study in patients treated with low-dose PTCy (14.5 mg/kg on days 3 and 4) in ATG/granulocyte colony-stimulating factor (G-CSF)-based regimen and compared the results to the contemporary cohort of patients without low-dose PTCy (ATG cohort). (biomedcentral.com)
  • Recently, we established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse. (biomedcentral.com)
  • This protocol consisted of a myeloablative conditioning (MAC) regimen containing cytarabine, busulfan, Cy combined with standard-dose ATG/G-CSF (the so-called Beijing protocol), and followed by low-dose PTCy (14.5 mg/kg on days 3 and 4 after HCT) for haplo-HCT recipients. (biomedcentral.com)
  • However, cyclophosphamide is still used either as a single agent or as adjuvant therapy to treat lymphomas, and breast and ovarian cancers at much lower doses. (monash.edu)
  • 1 In an attempt to reduce the neutropenia and maintain the high response rate of standard-dose FCR, we conducted a prospective phase 2 clinical trial in untreated CLL patients using lower doses of FC and higher dose of R followed by R maintenance until progression or up to 2 years (FCR-Lite). (ashpublications.org)
  • Cyclophosphamide and other alkylating agents are now used at lower doses to treat many types of cancer, including breast, ovarian, and pediatric cancers. (medindia.net)
  • Scholars@Duke publication: Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma. (duke.edu)
  • Fifty-five patients with refractory NHL and 13 with untreated, high-risk NHL were administered one cycle of daily cyclophosphamide 1.5 g/m2 intravenously on days 1-4 and etoposide 300 mg/m2 intravenously every 12 hours on days 1-3. (duke.edu)
  • In idiopathic pemphigus vulgaris and pemphigus foliaceus, high doses of systemic corticosteroids may be needed. (medscape.com)
  • Generally, it is used in conjunction with low doses of systemic corticosteroids. (medscape.com)
  • Also, patients with higher doses of JCAR17 had an improved ORR/CR, associated with higher CD8+ cell expansion, suggesting a durable remission. (medpagetoday.com)
  • Alkylating agents are more likely to affect the reproductive organs when given at higher doses. (kidshealth.org)
  • Prednisone in doses varying from 40 to 400 mg has been used in the treatment of pemphigus, the higher doses being required for 5-10 weeks for disease control [ 2 ]. (cdlib.org)
  • In this review, we highlight the potential for improving the efficacy of low dose cyclophosphamide by combining insights on the mechanisms of cyclophosphamide-mediated cytotoxicity, and how these cytotoxic effects of cyclophosphamide influence T cell function, thereby contributing to anti-tumour immunity. (monash.edu)
  • Purpose: Low-dose metronomic chemotherapy is an emergent treatment schedule in which low doses of cytotoxic agents are given orally continuously, with no or short drug-free intervals. (scirp.org)
  • The efficacy of low dose cyclophosphamide is primarily due to its ability to promote anti-tumour immunity, by selectively depleting regulatory T cells and enhancing effector T cell function. (monash.edu)
  • Recently, results of a prospective trial have been available which analyze the efficacy of combined use of low-dose ATG and 1-day high-dose PTCy (50 mg/kg at + 3 days) in preventing GVHD among haplo patients [ 17 ]. (biomedcentral.com)
  • The scope of the study was to compare low-dose Cy plus G-CSF versus intermediate-high-dose Cy plus G-CSF versus G-CSF alone for SC mobilization in MM, in terms of efficacy and safety. (univpm.it)
  • Doses of over 75 mg do not increase therapeutic effects. (medscape.com)
  • indicate tative comparisons of carcinogens been narrowed and their therapeutic that no agents classified as carci- with respect to potency in humans use has declined, with the possible nogenic to humans (Group 1) are and in experimental animals are exception of cyclophosphamide. (who.int)
  • ONTRUZANT ® was first approved as a 150 mg single-dose vial by FDA in January 2019 across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. (biospace.com)
  • 0.001) correlated with renal and systemic CL of CYC, respectively, and negatively correlated with dose corrected AUC. (nih.gov)
  • For optimal dosing of CYC in patients with renal insufficiency, the severity of renal impairment and the use and timing of hemodialysis have to be considered. (nih.gov)
  • Small doses are indicated initially in patients with small body size, elderly patients, and persons with renal or liver disease. (medscape.com)
  • Renal function should be assessed routinely for potential dose evaluation. (medscape.com)
  • Malignant lymphoma - mixed small and large cell: (single agent) 40 to 50 mg/kg IV in divided doses over 2 to 5 days OR 10 to 15 mg/kg IV every 7 to 10 days OR 3 to 5 mg/kg IV twice weekly. (wikidoc.org)
  • More than 60 years ago, British physician Denis Parsons Burkitt and his associates achieved one of the signal successes in cancer medicine when they cured children in sub-Saharan Africa with a form of lymphoma by treating them with high doses of the chemotherapy drug cyclophosphamide. (medindia.net)
  • It became a mainstay of cancer treatment after Burkitt and others used high doses to cure children with what's now known as Burkitt lymphoma - which had a 100% mortality rate at the time - sometimes with only one dose. (medindia.net)
  • Although high doses of cyclophosphamide and other alkylating agents may be too toxic for patients with diseases other than Burkitt lymphoma, researchers are investigating agents that mimic their ability to stress cancer cells, but with milder side effects. (medindia.net)
  • Obinutuzumab 1000 mg was administered intravenously on Day (D)1 (dose split D1‒2), D8 and D15 of Cycle (C)1, and D1 of C2-6 (28-day cycles). (nature.com)
  • The majority of NK-1 receptor antagonist doses are administered intravenously in the United States, and with the introduction of Varubi IV, we now offer healthcare providers a unique, easy-to-use option that fits well into standard operating practices of a chemotherapy clinic or hospital," Mary Lynne Hedley, PhD, president and COO of Tesaro, said in a press release. (pharmacytimes.com)
  • For fluorouracil: Liver function should be assessed prior to each cycle for potential dose evaluation. (medscape.com)
  • Intravenous pulse administration of cyclophosphamide (CYC) has been successfully used for the treatment of various autoimmune diseases. (nih.gov)
  • endovascular management has been andeyelesion).Shewasprescribed750 diagnosis is made on the basis of the attempted for treatment of vascular in- mg pulse cyclophosphamide monthly, criteria proposed by the International volvement. (who.int)
  • These results suggested that ATG/PTCy (low-dose) can reduce both acute and chronic GVHD as compared with standard ATG-based prophylaxis using maternal donor or collateral relatives at particular high GVHD risk. (biomedcentral.com)
  • In this prospective trial, results indicated that low-dose PTCy is sufficient to lower acute GVHD in mouse model, partly due to the boosting of fast regulatory T cell (Treg) reconstitution. (biomedcentral.com)
  • One patient treated at the highest dose level of doxorubicin (175 mg/m 2 ) developed symptoms of mild congestive heart failure following two cycles of chemotherapy. (elsevierpure.com)
  • Average cumulative dose was also calculated for early (cycles 1-3) and late (cycles 4-6) chemotherapy. (jnccn.org)
  • Cyclophosphamide may interfere with normal menstrual cycles and sperm production, potentially leading to permanent infertility. (onlinepharmaciescanada.com)
  • Such combination therapy may be most useful when "metronomic" doses of antineoplastic drugs are used, thereby potentially avoiding some of the immunosuppressive effects of these drugs. (ox.ac.uk)
  • Cyclophosphamide is a antineoplastic , immunosuppressive agent that is FDA approved for the treatment of malignant diseases , minimal change nephrotic syndrome in pediatric patients. (wikidoc.org)
  • Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. (ox.ac.uk)
  • Combining this immunotherapeutic regime with metronomic delivery of CTX resulted in antitumor activity that was dramatically enhanced over either treatment administered alone and was also significantly greater than combining immunotherapy with CTX administered by a maximum tolerated dose regime. (ox.ac.uk)
  • Duration of low-dose metronomic chemotherapy was also correlated with the variables analyzed and treatment outcomes. (scirp.org)
  • In metronomic chemotherapy, small doses of drugs are used daily. (marvistavet.com)
  • The discovery resolves long-standing questions about how cyclophosphamide and other alkylating agents - among the oldest and most widely used types of chemotherapy - work, and suggests a novel way of sparking an immune system strike on certain cancers. (medindia.net)
  • Researchers discovered, for example, that while high doses are much more effective against certain cancers than low doses, they inflict about the same amount of DNA damage, suggesting that something else comes into play at high doses. (medindia.net)
  • Three groups of mice, the negative and positive control groups containing each 12 males and 12 females and the test material group containing 7 mice per sex and sampling time for each of the three doses used (total in the test material group: 42 males and 42 females). (europa.eu)
  • Sixty mice were divided into five groups, and the mice were injected with cyclophosphamide to establish an immunosuppression model except for those in the common group. (hindawi.com)
  • Single agent: 1 to 5 mg/kg/day ORALLY, for both initial and maintenance dosing. (wikidoc.org)
  • Cyclophosphamide should be taken orally in tablet form, preferably with a meal to avoid stomach upset. (onlinepharmaciescanada.com)
  • abstract = "Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. (monash.edu)
  • Compared to effecter T cells, regulatory T cells have metabolic adaptations that make them more susceptible to cyclophosphamide-mediated cytotoxicity. (monash.edu)
  • Cyclophosphamide was just the eighth anti-cancer drug to enter standard therapy when it was approved by the U.S. Food and Drug Administration in 1954. (medindia.net)
  • When cyclophosphamide is used to treat nephrotic syndrome, it works by suppressing your body's immune system. (medlineplus.gov)
  • The weight loss and immune organ index decline caused by cyclophosphamide could be reversed by MP. (hindawi.com)
  • Cyclophosphamide dose in excess spurs immune system attack on the cells apart from killing the cancer cells directly, according to a new research published in the journal Cancer Discovery . (medindia.net)
  • The study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver. (sciencedaily.com)
  • Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver. (sciencedaily.com)
  • High dose cyclophosphamide alone may provide long term control of some patients with nodular lymphomas. (karger.com)
  • Administer high doses with caution, and closely observe the patient for response. (medscape.com)
  • In addition, low-dose PTCy could augment the protective effect of ATG on GVHD both in mouse and human sets while ensuring high rates of engraftment and keeping disease control [ 18 ]. (biomedcentral.com)
  • We retrospectively analyzed 422 MM patients undergoing SC mobilization in 6 Italian centers, including 188 patients who received low-dose Cy (LD-Cy group, defined as 2 g/m2), 163 patients who received intermediate-high-dose Cy (HD-Cy group, defined as ≥ 3 g/m2), and 71 patients who received G-CSF alone (G-CSF group). (univpm.it)
  • At high doses, cyclophosphamide and other alkylating agents blur the line between chemotherapy and immunotherapy. (medindia.net)
  • Our results show that, at high doses, cyclophosphamide and other alkylating agents blur the line between chemotherapy and immunotherapy," said Dana-Farber's David Weinstock, MD, the senior author of the study. (medindia.net)
  • In the new study, investigators focused on the effect of high doses of cyclophosphamide on macrophages - cells that, under the right conditions, eat infected cells or cells in the process of dying. (medindia.net)
  • The problem is, most adults can't tolerate high doses of chemotherapy because their organs are already damaged and they don't have a sibling with an exact tissue match. (medlineplus.gov)
  • Rather, its genotoxic effects are limited to indirect clastogenicity occurring in select cell types, and only when high dose and time thresholds are exceeded. (cdc.gov)